Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12681552 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TSHRCCR8KCNH2HTR1A | |
| SCHEMBL1695785 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHRCCR8KCNH2HTR1A | |
| SCHEMBL8400146 | 0.79 | AHR (0.31) | — | |
| SCHEMBL1690118 | 0.79 | ALDH1A1 (0.40) | ALDH1A1TSHRCCR8KCNH2 | |
| SCHEMBL18970159 | 0.79 | GABRA1 (0.44) | ALDH1A1TSHRCCR8KCNH2 | |
| SCHEMBL25844897 | 0.78 | MPO (0.41) | HTR1A | |
| SCHEMBL18558014 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TSHRCCR8KCNH2 | |
| SCHEMBL11021936 | 0.75 | AHR (0.45) | ALDH1A1TSHRHTR1A | |
| SCHEMBL14586296 | 0.74 | ALDH1A1 (0.39) | ALDH1A1MAPK1KMT2ATSHRCCR8 | |
| SCHEMBL18719369 | 0.74 | ALDH1A1 (0.37) | ALDH1A1TSHRCCR8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | GPR55, GPR65, GPR4 | ALDH1A1 1764/4885MAPK1 1465/4885KMT2A 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.